The study showed that Pyrotinib combined with Trastuzumab can effectively reduce serum levels of CEA, CA153, CA125, CA19-9, improve tumor response effect, and is not associated with the increase in side effects in patients with HER-2 positive BC. This evidence concerns the gene CEACAM5 and breast cancer.